Format

Send to

Choose Destination
See comment in PubMed Commons below
Proc (Bayl Univ Med Cent). 2006 Jul;19(3):281-4.

Exenatide (Byetta) as a novel treatment option for type 2 diabetes mellitus.

Author information

  • 1Department of Pharmacy Services, Baylor University Medical Center, Dallas, Texas, USA. RoberBo@BaylorHealth.edu

Abstract

Exenatide is the first drug in the incretin mimetic class and is indicated for treatment of type 2 diabetes mellitus. Although structurally similar to the native glucagon-like peptide, this synthetic form has a much longer duration of action. Randomized trials have shown exenatide to be efficacious in improving glycemic control when combined with either metformin or a sulfonylurea. The dose is initially 5 mcg subcutaneously twice daily and may be titrated to 10 mcg subcutaneously twice daily to achieve better diabetes management. Nausea, vomiting, and diarrhea were the most common adverse events reported with exenatide therapy. Exenatide is not associated with hypoglycemia, which may provide advantages over adding insulin to a sulfonylurea or metformin.

PMID:
17252050
PMCID:
PMC1484540
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Support Center